Drug intelligence / Profile preview

iMBP-001

Development stage: Preclinical
Lead developer: iMetabolic Biopharma
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes

Overview

iMBP-001 is a preclinical biological product developed by iMetabolic Biopharma Corp. using its proprietary iPlatform technology, formulated as a multidomain recombinant fusion protein designed as a metabolic inhibitor antagonist to preserve lipase activity. It targets hyperlipoproteinemia type I (also known as familial chylomicronemia syndrome), a congenital disorder characterized by impaired clearance of chylomicrons leading to severe hypertriglyceridemia and risk of acute pancreatitis; an evolved version focuses on lipoprotein particle reduction for atherosclerotic cardiovascular disease (ASCVD).[1][2][3][5]

Other names: iMBP 001iMBP001iMBP-001

Targets

Remnant lipoprotein particles

Beyond the preview

Go deeper on iMBP-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iMBP-001.

Explore the full profile